BioMarin Pharmaceutical Scheduled to Report Q3 2026 Earnings
BioMarin Pharmaceutical (BMRN) is set to release its third-quarter 2026 financial results on Monday, November 2, following the close of the market. Investors are closely watching for performance metrics as the company navigates significant year-over-year shifts in both profitability and top-line growth. Market consensus currently projects a revenue estimate of $1.02 billion, representing a substantial 31.4% increase compared to the previous year. However, earnings per share (EPS) are expected to be -$0.11, marking a sharp decline of approximately 191.7% year-over-year.
Tickers: $BMRN